LGD-2941
LGD-2941 is a Selective Androgen Receptor Modulator (SARM) that is currently under investigation for its potential applications in the treatment of osteoporosis and muscle wasting diseases. It is being developed by Ligand Pharmaceuticals, a biopharmaceutical company based in San Diego, California.
History[edit]
LGD-2941 was first synthesized by Ligand Pharmaceuticals as part of their ongoing research into SARMs. The compound was identified as a promising candidate due to its high selectivity for the androgen receptor, which suggested potential applications in the treatment of conditions characterized by muscle wasting or bone loss.
Mechanism of Action[edit]
As a SARM, LGD-2941 works by selectively binding to the androgen receptor, a type of nuclear receptor that is activated by binding to androgens, such as testosterone and dihydrotestosterone. By selectively binding to the androgen receptor, LGD-2941 can stimulate anabolic activity in muscles and bones without affecting other tissues, thereby avoiding many of the side effects associated with traditional anabolic steroids.
Clinical Trials[edit]
LGD-2941 has undergone several phases of clinical trials to evaluate its safety and efficacy. Early results have shown promise, with the compound demonstrating significant increases in lean body mass and bone mineral density in animal models. However, further research is needed to fully understand the potential benefits and risks of this compound in humans.
Potential Applications[edit]
The primary potential applications of LGD-2941 are in the treatment of osteoporosis and muscle wasting diseases. By stimulating anabolic activity in muscles and bones, LGD-2941 could potentially help to increase muscle mass and bone density in patients suffering from these conditions. However, further research is needed to confirm these potential benefits and to determine the optimal dosing regimen.
See Also[edit]
- Selective Androgen Receptor Modulator
- Osteoporosis
- Muscle wasting
- Ligand Pharmaceuticals
- Androgen receptor
- Clinical trials
-
LGD-2941
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
